WebOct 18, 2016 · SteadyMed Therapeutics (NSDQ:STDY) today detailed the development of its lead drug candidate, Trevyent (treprostinil sodium), for the treatment of pulmonary arterial hypertension using its PatchPump tech at the Parenteral Drug Assn. Conference in Huntington Beach, Calif.. PatchPump is the 1st single-use, wearable, pre-filled pump and … WebOct 3, 2024 · SteadyMed reported positive safety and tolerability data from the study. Trevyent was granted Orphan Drug Designation by the FDA in January 2016, and an NDA …
SteadyMed Raises $30 Million in Private Placement
WebApr 30, 2024 · SteadyMed has licensed Trevyent rights in Europe, Canada, and the Middle East to Cardiome. United Therapeutics said Trevyent would complement its portfolio of marketed and pipeline products for ... WebThe company’s first drug device combination product candidate is known as Trevyent™ and was developed to treat patients with pulmonary arterial hypertension (PAH). SteadyMed’s single-use product is designed to accurately and continuously deliver a subcutaneous infusion of the drug treprostinil 24 hours a day, every day, with each Trevyent™ unit … tiffany buffkin
SteadyMed Therapeutics - Crunchbase Company Profile & Funding
WebApr 5, 2024 · SAN RAMON, Calif., April 05, 2024 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product … WebDec 8, 2024 · The testing is designed to confirm product performance under various conditions on the final, to-be-marketed, Trevyent product. SteadyMed has begun the pre … WebTREVYENT SteadyMed, Ltd. USPTO Trademarks › SteadyMed, Ltd. › Trevyent Application #88644814. Application Filed: 2024-10-07. Trademark Application Details. The mark … the matt rebecca channel